Navigation Links
Targeting the protein AEG1 impairs human liver cancer growth in mice
Date:2/16/2009

Hepatocellular carcinoma (HCC) is a highly aggressive form of liver cancer and one of the 5 most common cancers worldwide. Devanand Sarkar and colleagues, at Virginia Commonwealth University School of Medicine, Richmond, have now identified a gene that is expressed at high levels in human HCC tumor samples and generates a protein important for HCC progression. They therefore suggest that targeting this gene (AEG1), or the protein that it generates, might provide a new therapeutic strategy for the treatment of HCC.

In the study, human liver cells were found to express only low levels of the protein AEG1, whereas human HCC tumor samples expressed very high levels. This was associated with an increase in the number of copies of the AEG1 gene in human HCC tumor samples. Functionally, human liver cell lines engineered to overexpress AEG1 grew faster than nonengineered cells and developed into highly aggressive tumors when transplanted into mice. In addition, knocking down levels of AEG1 in human HCC cell lines after they had been allowed to form a tumor in mice limited further growth. Further analysis revealed that the effects of AEG1 were mediated, in part, via its ability to activate the Wnt signaling pathway.


'/>"/>

Contact: Karen Honey
press_releases@the-jci.org
215-573-1850
Journal of Clinical Investigation
Source:Eurekalert

Page: 1

Related medicine news :

1. Tobacco Companies Targeting Teens, Study Says
2. APIC 2009 Targeting Zero Initiative Offers Practical Tools, Evidence-Based Elimination Strategies to Prevent the Deadliest Healthcare-Associated Infections
3. Targeting Cancers Own Stem Cells to Fight Recurrence
4. Researchers create smaller, brighter probe tailored for molecular imaging and tumor targeting
5. Health Care Service Corporation Finds Success With Innovative Program Targeting Obesity Epidemic
6. Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies
7. EGFR-targeting antibody licensed to Abbott
8. Tackling a hard-to-treat childhood cancer by targeting epigenetic changes
9. Tackling Hard-to-treat Childhood Cancer by Targeting Epigenetic Changes
10. NO on Prop 8 Campaign Slams Dishonest Mailer Targeting African-American Voters
11. Norwegian American Hospital Launches Awareness Campaign Targeting Hispanic, African-American and General-Market Moms
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... ... authorized OSHA Training Institute Education Center headquartered in Northern California, has issued an ... extreme heat at their worksites. Employers with workers exposed to high temperatures ...
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal ... Final Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. ... Cut Pro X users can now reveal the media of their split screens ...
(Date:6/27/2016)... ... ... TherapySites, the leading website and online marketing ... Association. This new relationship allows TherapySites to continue to extend their online ... and promotional offers. , "TCA is extremely excited about this new partnership, as ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... its strategic partnership with Connance, a healthcare industry leader providing predictive analytics ... proprietary technology combine to provide health systems, hospitals and ambulatory surgical centers ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... to revolutionize the emergency ambulance transport experience for the millions of people who ... Uber has disrupted the taxi industry through the use of technology. Now, SmartEMS ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... Australia,s successful biotechnology scientists, Dr Graham ... Noxopharm Limited [ABN 50 608 966 123] ("Noxopharm"). Noxopharm is seeking ... ASX. Noxopharm is a clinic-ready company with its first ... study later this year. NOX66 ... cancer patients - the ability of cancers to become resistant to ...
(Date:6/26/2016)... Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) announced ... Act of 1976, as amended ("HSR"), with respect to ... CPXX ) expired effective June 24, 2016, ... previously announced on May 31, 2016, Jazz Pharmaceuticals and ... Jazz Pharmaceuticals has commenced a tender offer for all ...
(Date:6/26/2016)... Ontario , June 27, 2016  VMS Rehab ... Company,s Board will take whatever measures required to build ... Company,s stock which is currently listed on the OTC ... Wexler, Company Chairman and CEO, "We are seeing an ... difficult to understand, not only by the Company, but ...
Breaking Medicine Technology: